Pulmatrix (NASDAQ:PULM) Shares Cross Above 50 Day Moving Average – Should You Sell?

Pulmatrix, Inc. (NASDAQ:PULM)’s share price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $7.44 and traded as high as $7.80. Pulmatrix shares last traded at $7.50, with a volume of 7,163 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Pulmatrix in a research note on Sunday, January 5th. They set a “hold” rating on the stock.

Pulmatrix Stock Down 1.7 %

The firm has a market capitalization of $27.27 million, a price-to-earnings ratio of -2.83 and a beta of 1.66. The stock’s 50-day moving average price is $7.47 and its 200 day moving average price is $5.17.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Friday, March 21st. The biotechnology company reported ($0.54) EPS for the quarter. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.

Institutional Trading of Pulmatrix

A hedge fund recently raised its stake in Pulmatrix stock. Geode Capital Management LLC lifted its stake in shares of Pulmatrix, Inc. (NASDAQ:PULM) by 24.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,871 shares of the biotechnology company’s stock after buying an additional 7,290 shares during the quarter. Geode Capital Management LLC owned about 1.01% of Pulmatrix worth $257,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.